Nanosonics (ASX: NAN) — Perfil da empresa, notícias e dados financeiros
Nanosonics develops automated disinfection technology for ultrasound probes, setting a global standard in infection prevention.
Nanosonics
Nanosonics is an Australian medical technology company focused on the development and commercialization of automated infection prevention and decontamination solutions. The company designs, manufactures, and distributes point-of-care automated high-level disinfection systems for ultrasound probes under the trophon brand, as well as digital traceability systems and consumables. Nanosonics also develops automated cleaning technology, such as Coris, for flexible endoscope reprocessing to reduce healthcare-associated infections and remove complex biofilm. The company supplies its healthcare infection control solutions, clinical education, and software platforms to hospitals and medical facilities across North America, Europe, and the Asia-Pacific region.
Resumo
Operações
Produtos e/ou serviços de Nanosonics
- Ultrasound probe disinfection systems: Automated point-of-care high-level disinfection devices utilizing proprietary vaporized hydrogen peroxide mist technology to reprocess ultrasound transducers, helping healthcare providers meet clinical infection prevention standards and mitigate cross-contamination risks across medical facilities.
- Infection prevention consumables and accessories: Specialized single-use hydrogen peroxide disinfectant cartridges, chemical indicators, cleaning wipes, probe covers, and accessory hardware required for the operation, validation, and routine maintenance of automated ultrasound transducer high-level disinfection hardware systems.
- Digital traceability and audit software: Integrated software and device tracking platforms that log disinfection cycles, record operator interactions, capture ultrasound probe serial numbers, and generate automated compliance audit trails for hospital infection control and quality assurance management.
- Automated endoscope cleaning platforms: Advanced automated reprocessing technology designed to clean complex reusable endoscope channels, targeting the removal of resistant bacterial biofilm from narrow lumened instruments prior to high-level disinfection or sterilization procedures in healthcare settings.
- Healthcare customer support and technical services: Field maintenance, equipment calibration, annual validation, spare parts replacement, and direct customer support programs provided to healthcare facilities to maintain operational uptime and ensure ongoing regulatory and performance compliance of installed equipment.
- Clinical education and training programs: Comprehensive infection prevention training, clinician certification, and educational resources delivered through dedicated learning portals and academies to standardize reprocessing workflows and train medical personnel on safe infection control practices.
equipe executiva do Nanosonics
- Michael C. KavanaghCEO, President, MD & Executive Director
- Jason BurrissChief Financial Officer
- Rod LopezChief Operating Officer
- Derek MinihaneChief Technology Officer
- Sunny PillaiChief Information Officer
- Jonathan BurdachChief Medical Affairs & Scientific Officer
- Catherine StrongHead of Investor Relations & Corporate Communications
- Matthew CarbinesGeneral Counsel & Company Secretary
- Kimberly HillChief Marketing Officer & Regional President of Asia Pacific
- Jodi SampsonChief People & Culture Officer
Comunicados recentes
O que a Nanosonics (NAN) comunicou ao mercado, do mais recente para o mais antigo.
- Update - Notification of buy-back - NAN
- Update - Notification of buy-back - NAN
- Update - Notification of buy-back - NAN
- Update - Notification of buy-back - NAN
- 2026 AGM Notice of Meeting
- Update - Notification of buy-back - NAN
Principais indicadores financeiros
Resultados divulgados pela Nanosonics, em AUD.
- Cap. de mercado
- 906,5 mi
- Receita (TTM)
- 203,9 mi
- P/L
- 50.5
- LPA (diluído, TTM)
- 0.1
- Dividend yield
- —
- Margem de lucro
- 8.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 203,5 mi | 15 mi | 17,8 mi | |
| 198,9 mi | 8,9 mi | 20,7 mi | |
| 171,6 mi | 9,1 mi | 13 mi | |
| 167,5 mi | 18 mi | 19,9 mi |